Literature DB >> 22941561

Influence of human immune cells on cancer: studies at the University of Colorado.

Tullia C Bruno1, Jena D French, Kimberly R Jordan, Oscar Ramirez, Trisha R Sippel, Virginia F Borges, Bryan R Haugen, Martin D McCarter, Allen Waziri, Jill E Slansky.   

Abstract

There will be over half a million cancer-related deaths in the United States in 2012, with lung cancer being the leader followed by prostate in men and breast in women. There is estimated to be more than one and a half million new cases of cancer in 2012, making the development of effective therapies a high priority. As tumor immunologists, we are interested in the development of immunotherapies because the immune response offers exquisite specificity and the potential to target tumor cells without harming normal cells. In this review, we highlight the current advances in the field of immunotherapy and the current work being completed by laboratories at University of Colorado School of Medicine in multiple malignancies, including breast cancer, lung cancer, melanoma, thyroid cancer, and glioblastoma. This work focuses on augmenting the anti-tumor response of CD8 T cells in the blood, lymph nodes, and tumors of patients, determining biomarkers for patients who are more likely to respond to immunotherapy, and identifying additional anti-tumor and immunosuppressive cells that influence the overall response to tumors. These collaborative efforts will identify mechanisms to improve immune function, which may elucidate therapeutic targets for clinical trials to improve patient health and survival.

Entities:  

Mesh:

Year:  2013        PMID: 22941561      PMCID: PMC3984131          DOI: 10.1007/s12026-012-8346-y

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  123 in total

1.  THE RELATION OF THYROID CARCINOMA AND CHRONIC THYROIDITIS.

Authors:  R N HIRABAYASHI; S LINDSAY
Journal:  Surg Gynecol Obstet       Date:  1965-08

Review 2.  Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

Authors:  Alberto J Montero; Claudia Marcela Diaz-Montero; Christos E Kyriakopoulos; Vincenzo Bronte; Susanna Mandruzzato
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

Review 3.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

4.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

6.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

7.  Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood.

Authors:  Camilla Jandus; Gilles Bioley; Daniel E Speiser; Pedro Romero
Journal:  Cancer Immunol Immunother       Date:  2008-04-15       Impact factor: 6.968

8.  Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; James A Thompson; Bruce R Ksander; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2008-03-06       Impact factor: 6.968

Review 9.  Systematic review of medical treatment in melanoma: current status and future prospects.

Authors:  Claus Garbe; Thomas K Eigentler; Ulrich Keilholz; Axel Hauschild; John M Kirkwood
Journal:  Oncologist       Date:  2011-01-06

10.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

View more
  8 in total

1.  Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Authors:  Francesca M Bosisio; James S Wilmott; Nathalie Volders; Marjorie Mercier; Jasper Wouters; Marguerite Stas; Willeke Am Blokx; Daniela Massi; John F Thompson; Richard A Scolyer; Nicolas van Baren; Joost J van den Oord
Journal:  Mod Pathol       Date:  2016-02-12       Impact factor: 7.842

Review 2.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

3.  Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment.

Authors:  Aliyah M Weinstein; Lu Chen; Emily A Brzana; Prashanti R Patil; Jennifer L Taylor; Kellsye L Fabian; Callen T Wallace; Sabrina D Jones; Simon C Watkins; Binfeng Lu; David F Stroncek; Timothy L Denning; Yang-Xin Fu; Peter A Cohen; Walter J Storkus
Journal:  Oncoimmunology       Date:  2017-04-28       Impact factor: 8.110

4.  Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model.

Authors:  Efthymia Papaevangelou; Dorota Smolarek; Richard A Smith; Prokar Dasgupta; Christine Galustian
Journal:  Immunotargets Ther       Date:  2020-07-27

5.  Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer.

Authors:  Yeonjoo Choi; Jin Won Kim; Kyung Han Nam; Song-Hee Han; Ji-Won Kim; Sang-Hoon Ahn; Do Joong Park; Keun-Wook Lee; Hye Seung Lee; Hyung-Ho Kim
Journal:  Gastric Cancer       Date:  2016-09-24       Impact factor: 7.370

Review 6.  Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.

Authors:  Ida Silvestri; Susanna Cattarino; Anna Maria Aglianò; Giulia Collalti; Alessandro Sciarra
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

7.  CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers.

Authors:  Chiara Tuccilli; Enke Baldini; Salvatore Sorrenti; Antonio Catania; Alessandro Antonelli; Poupak Fallahi; Francesco Tartaglia; Susi Barollo; Caterina Mian; Andrea Palmieri; Giovanni Carbotta; Stefano Arcieri; Daniele Pironi; Massimo Vergine; Massimo Monti; Salvatore Ulisse
Journal:  Int J Endocrinol       Date:  2018-07-05       Impact factor: 3.257

8.  Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis.

Authors:  Rixin Zhang; Tiegang Li; Weiqi Wang; Wenqiang Gan; Silin Lv; Zifan Zeng; Yufang Hou; Zheng Yan; Min Yang
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.